ALKS
Alkermes plc
NASDAQ · Healthcare · Biotechnology · IE
$46.10
−1.66%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- 68.37x
- P/E 2028E
- 37.60x
- P/S forward
- 4.12x
Trailing multiples
Trailing twelve months
- P/E TTM
- 114.39x
- PEG TTM
- —
- Price / book
- 4.28x
- Price / sales
- 4.64x
- Price / cash flow
- 30.79x
Enterprise value
- Enterprise value
- $8.6B
- EV / sales
- 5.19x
- EV / EBITDA
- 39.67x
- EV / EBIT
- 73.75x
- Market cap
- $7.7B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026